Metabolic effects of thiazide and 1,25-(OH)2 vitamin D in postmenopausal osteoporosis
- PMID: 8338977
- DOI: 10.1007/BF01623678
Metabolic effects of thiazide and 1,25-(OH)2 vitamin D in postmenopausal osteoporosis
Abstract
It was previously shown that the stimulation of intestinal calcium absorption by exogenous 25-hydroxyvitamin D (25-OHD) in postmenopausal women with osteoporosis was attenuated when thiazide was added, probably due to the suppression of endogenous synthesis of 1,25-(OH)2 vitamin D (1,25-(OH)2D). To test whether the above attenuation could be averted if exogenous 1,25-(OH)2D replaced 25-OHD, 10 women with postmenopausal osteoporosis participated in a three-phase study comprising control (pretreatment), treatment with 1,25-(OH)2D 0.5 microgram/day for 4 weeks, and combined 1,25-(OH)2D and trichlormethiazide (TZ) 2 mg/day for 4 weeks. The 1,25-(OH)2D treatment significantly increased serum 1,25-(OH)2D from 60 +/- 7.2 (SD) to 154 +/- 48 pmol/l, fractional intestinal calcium absorption (alpha) from 0.386 +/- 0.055 to 0.613 +/- 0.081, and urinary calcium from 3.7 +/- 0.8 to 6.6 +/- 1.9 mmol/day. Addition of TZ significantly reduced urinary calcium from 6.6 +/- 1.9 to 4.8 +/- 1.3 mmol/day, without changing alpha (0.613 +/- 0.081 to 0.584 +/- 0.070), serum calcium or 1,25-(OH)2D (154 +/- 48 to 154 +/- 38 pmol/l). Thus, estimated calcium balance (absorbed minus urinary calcium, increased marginally to +5.6 mmol/day on 1,25-(OH)2D alone (p = 0.028) and significantly to +6.8 mmol/day on 1,25-(OH)2D+TZ, from the control value of +4.0 mmol/day. Seven patients who were treated long-term with combined 1,25-(OH)2D and TZ for 11-29 months maintained their alpha (0.593 +/- 0.099) and a marginally more positive estimated calcium balance (+6.4 mmol/day, p = 0.025 from the control phase). Moreover, there was a stability of bone density of radial shaft, femoral neck, and lumbar spine.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women.Calcif Tissue Int. 1990 Dec;47(6):332-7. doi: 10.1007/BF02555883. Calcif Tissue Int. 1990. PMID: 2292078
-
Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.Bone Miner. 1990 May;9(2):137-52. doi: 10.1016/0169-6009(90)90080-y. Bone Miner. 1990. PMID: 2161692 Clinical Trial.
-
Selective effects of thiazide therapy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias.Metabolism. 1980 Jan;29(1):13-7. doi: 10.1016/0026-0495(80)90091-8. Metabolism. 1980. PMID: 7351872
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Role of vitamin D, its metabolites, and analogs in the management of osteoporosis.Rheum Dis Clin North Am. 1994 Aug;20(3):759-75. Rheum Dis Clin North Am. 1994. PMID: 7984788 Review.
Cited by
-
Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis.Drugs Aging. 1994 Oct;5(4):300-17. doi: 10.2165/00002512-199405040-00006. Drugs Aging. 1994. PMID: 7827399 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources